Damayanthi Devineni

Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Sue Sha, Damayanthi Devineni, A. Ghosh et al. · Diabetes Obesity and Metabolism · 2011 · 292 citations

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

Damayanthi Devineni, Linda Morrow, Marcus Hompesch et al. · Diabetes Obesity and Metabolism · 2012 · 221 citations

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

Damayanthi Devineni, Christopher R. Curtin, David Polidori et al. · The Journal of Clinical Pharmacology · 2013 · 211 citations

Importance of Early Phase Insulin Secretion to Intravenous Glucose Tolerance in Subjects with Type 2 Diabetes Mellitus

Steven E. Kahn, Brenda K. Montgomery, W. Mike Howell et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 100 citations

Metabolism and Excretion of Canagliflozin in Mice, Rats, Dogs, and Humans

Rao N. V. S. Mamidi, Filip Cuyckens, Jie Chen et al. · Drug Metabolism and Disposition · 2014 · 63 citations